Latest Breaking News On - Mannin research inc - Page 1 : comparemela.com

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC

/PRNewswire/ Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its.

Georgen nikopoulosSusan quagginDenis corinKeith pinderPrnewswireq biomed incSecurities exchangeCq biomed incSourceq biomed incMannin research incMannin researchResearch incLooking statementsSecurities actSecurities exchange actBiomed media contactCq biomed inc

Financial Review: Q BioMed (OTCMKTS:QBIO) vs Indaptus Therapeutics (NASDAQ:INDP)

Q BioMed (OTCMKTS:QBIO – Get Rating) and Indaptus Therapeutics (NASDAQ:INDP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Profitability This table compares Q BioMed and Indaptus Therapeutics’ […]

New yorkUnited statesIntec parent incIndaptus therapeutics incCq biomed incAbiomed incTech solutions incMannin research incGet ratingIndaptus therapeuticsIndaptus therapeuticGiven indaptus therapeuticStrontium chlorideMannin researchIntec parentQ biomed

Q BioMed Inc says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets

Q BioMed Inc says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Cq biomed incMannin research incNew york basedStrontium chlorideAcute respiratory distress syndromeOrphan drug designationRare disease spaceOrphan drugAutism spectrumInvestigational new drug

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

/PRNewswire/ Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy and value proposition for its.

United statesDenis corinKeith pinderCq biomed incSourceq biomed incMannin research incDevelopment platformCorporate developmentSecurities exchangeMannin research platform drugsProduct revenue growthResearch platform drugsKidney diseasesMannin researchAcute respiratory distress syndromeLiver cancer

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

/PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues,.

United statesDenis corinKeith pinderIndian health servicesCq biomed incSourceq biomed incMannin research incSecurities exchangeUs departments of veteran affairsFederal salesVeteran affairsIndian healthPlatform drugsKidney diseasesAcute respiratory distress syndromeOrphan drug designation